Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.99% | 4.82% | 24.94% | 6.30% | -15.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.13% | 37.50% | 68.75% | 43.47% | 16.77% |
| Operating Income | -19.13% | -37.50% | -68.75% | -43.47% | -16.77% |
| Income Before Tax | -25.67% | -47.67% | -73.48% | -34.15% | -16.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.67% | -47.67% | -73.48% | -34.15% | -16.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.67% | -47.67% | -73.48% | -34.15% | -16.18% |
| EBIT | -19.13% | -37.50% | -68.75% | -43.47% | -16.77% |
| EBITDA | -19.45% | -38.01% | -69.77% | -44.15% | -16.88% |
| EPS Basic | -21.02% | -32.48% | -25.62% | 5.05% | 17.78% |
| Normalized Basic EPS | -21.05% | -32.48% | -25.66% | -3.23% | 17.79% |
| EPS Diluted | -21.02% | -32.48% | -25.71% | 5.05% | 17.78% |
| Normalized Diluted EPS | -21.05% | -32.48% | -25.66% | -3.23% | 17.79% |
| Average Basic Shares Outstanding | 3.83% | 11.48% | 38.08% | 41.29% | 41.31% |
| Average Diluted Shares Outstanding | 3.83% | 11.48% | 38.08% | 41.29% | 41.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |